Abstract: Chronic hepatitis C virus (HCV) infection is a leading cause of chronic liver diseases and hepatocellular carcinoma (HCC) worldwide. In the past few years, anti-HCV therapies have undergone a revolution with the approval of multiple direct-acting antivirals (DAAs), which enable interferon-free treatments with considerable improvement of sustained virologic response in patients. Today, DAAs have become the standard of care for HCV therapy. However, several limitations remain, which include access to therapy, treatment failure in a subset of patients and persistent risk of HCC development following cure in patients with advanced fibrosis. By targeting conserved host proteins involved in the HCV life cycle, hosttargeting agents (HTAs) offer opportunities for pan-genotypic antiviral approaches with a high barrier to drug resistance. Moreover, when applied in combination with DAAs, HTAs could improve the management of difficult-to-treat patients by acting through a complementary mechanism of action. In this review, we summarize the different HTAs evaluated in preclinical and clinical development and discuss their potential role for anti-HCV therapies.
Introduction
Hepatitis C virus (HCV) is a hepatotropic RNA virus, which belongs to the Flaviviridae family. 1 Chronic HCV infection is a major public health problem, affecting more than 150 million individuals worldwide. Chronically infected patients are at high risk for developing liver fibrosis, cirrhosis and hepatocellular carcinoma (HCC). In many parts of the world, HCV infection is the major cause of HCC and the leading indication for liver transplantation (LT). 2 There is no vaccine to prevent HCV infection. In the past, interferon (IFN)-based regimens were the standard of care for HCV infection, but only led to a sustained virologic response (SVR) in 50% of patients with serious adverse effects. 3 Recent approval of novel antivirals directly targeting the virus, named direct-acting antivirals (DAAs), have enabled IFN-free treatments with considerable SVR improvement (SVR rates over 90%). Although the development of DAAs has revolutionized HCV therapy, several limitations remain: these include limited access to therapy in the majority of infected patients, treatment failure in a subset of patients, potential adverse effects in patients with comorbidity and persistent HCC risk following SVR in patients with advanced fibrosis. 4 Targeting host factors required for virus infection is an attractive complementary strategy to address these challenges. An improved understanding of the viral life cycle based on the development of advanced HCV model systems has enabled the design of new molecules that target key factors of the HCV life cycle, named host-targeting agents (HTAs). 5 HTAs provide a broad antiviral activity with very high genetic barrier to drug resistance due to the extremely low mutational rate occurring within host cells. 5, 6 Several HTAs are now being evaluated in phase II and III clinical trials. Here, we review the different classes of HTAs in preclinical Limitations of DAA-based therapies Today, it is estimated that more than 90% of patients with chronic hepatitis C can be cured with DAA-based regimens. Clinical studies involving large numbers of patients confirmed excellent efficacy, safety and tolerability of the new DAA combinations. However, several challenges remain unsolved.
The most important limitation is probably the accessibility of DAA regimens. Indeed, access to DAAs is limited to less than 10% of patients with HCV infection, especially in low-resource countries. 16 Moreover, the management of special populations, or 'difficult-to-treat' patients still requires special attention. 17 One challenge remains the treatment of patients with advanced cirrhosis and decompensated liver disease. Recent studies revealed that patients with or without cirrhosis respond equally well to DAAs, whereas patients with advanced cirrhosis appear to have a reduced ability to clear the virus, leading to lower SVR rates in this population. 18, 19 For these patients, treatment regimens should be adapted to higher doses or longer treatment duration. In this regard, it is important to note that patients with advanced cirrhosis (Child-Pugh classes B and C) were excluded in many phase II and phase III clinical trials and fewer studies were conducted in patients with decompensated liver disease in the past. 8, [10] [11] [12] [20] [21] [22] Consequently, the dosage of DAAs, either alone or in combination, their efficacy and their safety have only been partially addressed in these special populations. Furthermore, several DAA-based regimens (e.g. the NS34A protease inhibitors simeprevir and asunaprevir) cannot easily be used in patients with decompensated cirrhosis because of their impaired drug-metabolizing capacity, leading to severe adverse effects. 19, 23, 24 DAA-based regimens can also be challenging for patients with advanced renal insufficiency who often need DAA dose adjustments. 19 Furthermore, few treatment options are available for patients with end-stage renal disease. Indeed, current recommendations only allow the use of grazoprevir (NS3/NS4A inhibitor) and elbasvir (NS5A inhibitor) in combination in these patients. 25, 26 Despite overall promising results, the optimal DAA combination, the treatment duration and treatment dosages in these special populations require further investigations.
Limitations in the application of DAA regimens also include certain viral genotypes. HCV genotype 3 is considered to be the most difficult-tocure genotype with DAA-based therapy. 27, 28 Currently available DAAs are less efficient against this genotype. Two regimens are recommended for the management of these patients: the combinations of daclatasvir and sofosbuvir or sofosbuvir and velpatasvir. The SVR rates are lower compared with other genotypes, ranging from 50% to 90% depending on the treatment history and the disease stage. 27-31 Interestingly, HCV genotype 3 is the second most prevalent genotype worldwide with high morbidity and mortality rates compared with other genotypes. 32 Therefore, additional studies are needed to improve new journals.sagepub.com/home/tag 3 therapeutic options for patients with HCV genotype 3 infection.
Another aspect that requires further studies is the persistent risk of HCC post cure in patients with advanced fibrosis or comorbidities. Although the risk of de novo HCC development is reduced after SVR, HCC can occur even more than 10 years following successful HCV clearance. 4, 33, 34 Evidence from several cohorts appears to suggest that post-SVR HCC development and recurrence may be more frequent after DAA treatment compared with IFN-based therapy, potentially due to a difference in host immune modulation between IFN-and DAA-treated patients. 4, 35 Given the increasing incidence of HCC and the urgent unmet needs for prevention and detection of HCC, alternative strategies for these populations should be explored. 7, 34 Although not an issue in the majority of treated patients, HCV resistance to DAAs can occur in a small minority of patients. HCV has a quasispecies distribution. The high replication rate of HCV (10 10 −10 12 virions per day in patients with chronic infection) and the low fidelity of its RNA polymerase (1.5-2.0 × 10 −3 base substitutions per genome site per year) result in a high degree of genetic variants. Therefore, patients are infected by a mix of distinct but closely related viral populations. 36 Viral polymorphisms can naturally appear in regions targeted by DAA and may confer DAA resistance. When a DAA treatment is administered, sensitive wild-type populations are completely inhibited while drug-resistant variants are rapidly selected, leading to treatment failure (breakthrough) or relapse after therapy. 17, 37 Moreover, DAAs from the same class share cross resistance, meaning that specific mutations can confer reduced susceptibility to all molecules from the same class, thereby limiting retreatment options. 17, 38 Consequently, more studies and clinical trials are ongoing to define the best retreatment strategies for patients with viral resistance or treatment failure.
Targeting of viral host-dependency factors to prevent and cure HCV infection
The HCV life cycle can be divided into three major steps: viral attachment and cell entry; viral translation and replication; and assembly and release of the new infectious virions (Figure 1 103 The precise mechanism of action is not yet fully understood. Some studies suggested that the anti-HCV activity of statins could be due to the inhibition of geranylgeranylation of cellular proteins rather than to the inhibition of cholesterol biosynthesis. 100, 104 Geranylgeranylation is a posttranscriptional modification that attaches geranylgeranyl groups produced through the cholesterol biosynthesis pathway to host proteins to facilitate their association with the host-cell membrane, which is essential for viral replication. 105 vitro. 120, 121 However, their suitability for antiviral treatment still needs to be investigated.
Inhibitors of HCV assembly and release
α-Glucosidase inhibitors The HCV particle consists of a nucleocapsid containing the viral RNA, surrounded by an ER-derived membrane where E1 and E2 glycoproteins are anchored as heterodimers. 43 In the ER, E1 and E2 proteins are highly glycosylated by α-glucosidases I and II, which ensure proper folding of these proteins. Celgosivir, a glucosidase I inhibitor, was shown to reduce virion production and viral infectivity in vitro. 122, 123 It also exhibited antiviral activity in preclinical trials and was investigated in a phase II clinical trial. Although this compound is not efficient as a monotherapy, it demonstrated a synergistic effect in combination with IFN-based therapies [ClinicalTrials.gov identifier: NCT00332176]. 122 The clinical trials for celgosivir were stopped as stated in the Migenix financial report for 2010.
Inhibitors of HCV core protein trafficking
Since HCV circulates as a LVP in the blood of patients with infection, viral assembly and egress of infectious LVP rely on host factors, which are required for lipid metabolism and VLDL production. Therefore, they represent potential targets for anti-HCV therapies. 39, 124, 125 Virus assembly is triggered by core protein recruitment on LD by the diglyceride acyltransferase I (DGAT-I). 126, 127 It was demonstrated that DGAT-I inhibitors efficiently suppress production of infectious viral particles in vitro while LD formation is not affected. Interestingly, quercetin, a natural flavonoid that inhibits DGAT-I, was reported to have anti-HCV properties. 128 In a phase I dose-escalation study, quercetin exhibited both high safety (up to 5 g/day) and high antiviral efficacy in patients with chronic infection. 129 Quercetin is widely available and cheap, and could thus be developed as an inexpensive adjuvant for HCV treatment. Recently, the antiviral efficacy of the DGAT-I inhibitor LCQ908/pradigastat was assessed in phase II clinical trials in patients with HCV infection. Pradigastat was also safe and well tolerated. However, the clinical study was prematurely interrupted for lack of efficacy: no significant change in serum viral RNA levels was observed in patients after pradigastat treatment compared with the placebo group. 130 More studies are now needed to determine whether the DGAT-I inhibitor could be beneficial for patients in combination with DAAs.
During HCV assembly, HCV core protein is recruited from LD to the viral assembly site. This process involves several host factors, including clathrin assembly protein complex 2 medium chain μ1 (AP2M1), which directly interacts with core protein. Furthermore, the adaptor-associated kinase 1 (AAK1) and the cyclin-associated kinase (GAK) are known to regulate core-AP2M1 interaction and are essential for HCV assembly. [131] [132] [133] Accordingly, Neveu and colleagues discovered that AAK1 and GAK inhibitors, including the approved anticancer drugs sunitinib and erlotinib, can block HCV assembly. 131, 132 However, these compounds were initially developed to target other kinases and could have adverse effects due to their lack of specificity. To overcome this problem, a more specific GAK inhibitor, isothiazolo [5,4-b] pyridine, was recently developed. This new drug efficiently inhibits HCV entry and assembly in vitro with limited off-target effects and has been proposed as an antiviral strategy. 133 
Inhibitors of host lipid metabolism
During the later stages of assembly, HCV coopts the VLDL pathway. 124, 134 Formation of VLDL as well as LVP requires the microsomal triglyceride transfer protein (MTP). This host enzyme mediates triglyceride incorporation into nascent LD and allows lipid loading of ApoB in the ER.
Compounds that inhibit the VLDL assembly pathway, such as MTP inhibitors or ApoB inhibitors, are therefore interesting candidates to block HCV assembly and release. 124, 134 In line with these observations, the MTP inhibitor naringenin, a grapefruit flavonoid, has been shown to inhibit VLDL secretion in vitro and in vivo as well as HCV secretion in cell culture. 135 More recently, a study demonstrated that the MTP inhibitor amiodarone also downregulates HCV assembly and release. 136 However, a recent report indicated that amiodarone could induce bradycardia in patients when administered in combination with DAAs. 96 Several other MTP inhibitors are currently being evaluated in clinical trials for the treatment of dyslipidemia but their in vivo efficacy against HCV remains to be demonstrated. [137] [138] [139] Interestingly, mipomersen, an antisense inhibitor 8 journals.sagepub.com/home/tag of ApoB synthesis used for the treatment of hypercholesterolaemia was also shown to efficiently block HCV morphogenesis in vitro. 140 Mipomersen now needs to be tested in vivo.
In 2011, Goldwasser and colleagues showed that naringenin blocks HCV assembly not only by inhibiting MTP but also by activating the peroxisome proliferator-activated receptor α (PPARα) in HCV-infected cells. 141, 142 PPARα is a nuclear transcription factor regulating several aspects of the lipid metabolism in the liver. Notably, its activation leads to increase of fatty acid oxidation and impairment of HCV assembly and release. 143, 144 During chronic HCV infection, the viral core protein inhibits PPARα activity to promote HCV replication. Thus, restoring PPARα activity constitutes an interesting strategy to inhibit HCV infection. 145, 146 Accordingly, several approved drugs targeting PPARα were shown to display antiviral activity against HCV. This holds true for resveratrol and its methylated form pterostilbene (two natural compounds extracted from grapes and blueberries) as well as for torimefene (a tamoxifene derivative). 146, 147 In addition, Fujita and collaborators demonstrated the efficacy of bezafibrate, another PPARα agonist commonly used against hyperlipidemia in patients with chronic HCV infection. 148 However, in 2013, Knop and colleagues observed that the beneficial effect of bezafibrate in patients is not due to a decrease in HCV RNA levels but rather to a significant reduction of liver enzymes and improved liver function in patients. 149 Finally, more recent studies corroborated the efficacy of bezafibrate in the regulation of lipid metabolism and in the reduction of viral loads in cell culture, indicating that further studies are needed to ascertain its potential for anti-HCV therapies. 150, 151 Clinical trials are needed to investigate the clinical antiviral efficacy of assembly inhibitors.
Future role of HTAs in HCV therapy
DAA-based treatment is standard of care for the management of patients with chronic HCV infection. Next-generation DAAs with an even higher barrier to resistance and pan-genotypic activity are currently under clinical development. 3 In this context, one can wonder about the positioning of HTAs in anti-HCV therapy. A key advantage of HTAs could be linked to the question of whether next-generation DAAs can address the limitations of currently licensed combination therapies
(patients who are difficult to treat, resistance, access and HCC risk). While it is expected that next-generation DAAs will indeed address several of these issues, it is likely that DAAs will not be able to address all of these remaining challenges.
Multiresistance, especially in patients with reinfection such as those who are drug abusers with limited compliance and have had multiple treatment courses, may require complementary compounds. This is already blatant for nosocomial bacterial infections in patients who are critically ill, in whom current antibiotics are no longer effective. HTAs may also prove useful to ameliorate current treatment approaches when combined with DAAs. 
